Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium | PHASE2 | COMPLETED | 56 | — | — | Mar 27, 2018 | Jul 15, 2019 | Nov 27, 2024 | 5 | United States |
Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).
Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84).
| Arm | Type | Description |
|---|---|---|
| VP-102 | EXPERIMENTAL | Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. |
| Name | Type | Description |
|---|---|---|
| VP-102 Cantharidin topical film forming solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments. |
| VP-102 Cantharidin, topical film forming solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments. |
Inclusion Criteria: 1. Be healthy, immunocompetent males or females at least 2 years of age and older for Cohort 1 and 12 years of age and older for Cohort 2. 2. Present with 1-6 common warts (verruca vulgaris) located anywhere on the body except for the following prohibited areas: the eye area (in...